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The UCH-L1 Gene Encodes Two Opposing Enzymatic
Activities that Affect -Synuclein Degradation
and Parkinson’s Disease Susceptibility
activity of UCH-L1, this form of PD was proposed to
result from a partial loss of UCH-L1 hydrolytic function.
However, several pieces of evidence suggest that sim-
ple loss of hydrolytic function does not completely ex-
plain the PD phenotype in this family. First, the mutation
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Harvard Medical School is not 100% penetrant; the father of the two affected
individuals and the presumed carrier of I93M did not65 Landsdowne Street
Cambridge, Massachusetts 02139 develop PD. Second, mice lacking functional UCH-L1
(the gracile axonal dystrophy [GAD] mouse) do not de-
velop a Parkinsonian phenotype (Kurihara et al., 2001;
Saigoh et al., 1999; Miura et al., 1993; Mukoyama et al.,Summary
1989; Oda et al., 1992; Wu et al., 1995). Neuronal loss
in the GAD mice occurs in the gracile tract as opposedThe assumption that each enzyme expresses a single
to the substantia nigra in PD and no Parkinsonian move-enzymatic activity in vivo is challenged by the linkage
ment disorder is observed.of the neuronal enzyme ubiquitin C-terminal hy-
In the course of a failed search for additional I93Mdrolase-L1 (UCH-L1) to Parkinson’s disease (PD).
mutants, a previously unrecognized polymorphism inUCH-L1, especially those variants linked to higher
the UCH-L1 gene (S18Y) was discovered and subse-susceptibility to PD, causes the accumulation of
quently found to be linked to a decreased susceptibility-synuclein in cultured cells, an effect that cannot be
to PD (Levecque et al., 2001; Maraganore et al., 1999;explained by its recognized hydrolase activity. UCH-
Momose et al., 2002; Satoh and Kuroda, 2001; Wang etL1 is shown here to exhibit a second, dimerization-
al., 2002). The S18Y polymorphism is relatively rare independent, ubiquityl ligase activity. A polymorphic
the European population (allele frequency is 14%–20%)variant of UCH-L1 that is associated with decreased
but common in the Japanese (39%–54%) and ChinesePD risk (S18Y) has reduced ligase activity but compa-
(50%) populations. Protection is dependent on therable hydrolase activity as the wild-type enzyme. Thus,
S18Y allele dosage; that is, homozygotes are at signifi-the ligase activity as well as the hydrolase activity of
cantly lower risk (relative risk of 0.31) than are heterozy-UCH-L1 may play a role in proteasomal protein degra-
gotes (relative risk between 0.55 and 0.81) (Levecquedation, a critical process for neuronal health.
et al., 2001; Maraganore et al., 1999; Satoh and Kuroda,
2001). The simplest explanation for these findings, thatIntroduction
S18Y is protective because it has the opposite effect
on UCH-L1 hydrolytic activity as I93M, is inconsistentUCH-L1 is an abundant neuronal enzyme (1%–2% of
with the predicted location of residue 18 on the proteinbrain protein [Wilkinson et al., 1989]) of unknown func-
surface, distal from the active site and the ubiquitintion. In vitro, UCH-L1 catalyzes hydrolysis of C-terminal
binding site (Figure 1; Johnston et al., 1997, 1999). Fur-ubiquityl esters and amides; peptide-ubiquityl amides
thermore, the fact that position 18 is one of only a feware the preferred substrates (Larsen et al., 1996, 1998).
residues that are not conserved between human andThis activity is presumed to be critical for cytoplasmic
other mammals (horse, mouse, and rat have Ala at posi-protein degradation, recycling free ubiquitin by cleaving
tion 18) suggests that residue 18 is not involved in theubiquitylated peptides that are the products of the pro-
normal “biological” activity of UCH-L1 and suggests theteasomal degradation of polyubiquitylated proteins
existence of a distinct pathological UCH-L1 activity. We(Larsen et al., 1996, 1998). The importance of the cyto-
set out to compare the properties of the high- andplasmic protein degradation pathway in Parkinson’s dis-
low-risk human polymorphic UCH-L1 variants, usingease (PD) is suggested by the fact that two gene prod-
-synuclein as a model substrate. In doing so, we dis-ucts that are linked to familial PD are sensitive to or
covered a novel ubiquitin-ubiquitin ligase activity ofinvolved in this pathway: -synuclein forms potentially
UCH-L1 that may also be important in PD pathogenesis.pathogenic aggregates (protofibrils) when its concentra-
The existence of this activity is inconsistent with thetion exceeds a critical threshold, and parkin is an E3
one gene-one enzyme paradigm and has important im-ligase that ubiquitylates -synuclein and other protein
plications regarding targeting UCH-L1 with anti-Parkin-substrates, tagging them for degradation and pre-
son’s disease drugs.venting this threshold from being reached (Lansbury and
Brice, 2002).
UCH-L1 was first linked to PD by an autosomal domi- Results
nant point mutation (I93M) that was identified in two
siblings with a strong family history of PD (Leroy et UCH-L1 and -Synuclein Colocalize with Synaptic
Vesicles and Can Be Coimmunoprecipitatedal., 1998). Since I93M decreases the in vitro hydrolytic
from Mammalian Brain
In an effort to localize UCH-L1 and identify potential1Correspondence: plansbury@rics.bwh.harvard.edu
substrates, synaptic vesicles were isolated from rabbit2 Present address: Montreal Neurological Institute, 3801 University
St., Montreal, Quebec H3A 2B4, Canada. brain using a standard method (Hell and Jahn, 1998).
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coimmunoprecipitated from the synaptic vesicle frac-
tion using a UCH-L1 antibody (Chemicon, pig polyclonal,
Figure 2B). In a separate experiment, UCH-L1 was iso-
lated from rat brain lysate using an anion exchange
column. A small fraction of the total -synuclein co-
eluted with UCH-L1. Fractions containing both UCH-L1
and -synuclein were treated with a UCH-L1 antibody
(Chemicon, rabbit polyclonal), an -synuclein antibody
(Transduction Lab), or buffer (as a control), and the anti-
body complexes were precipitated. The precipitated
complexes were dissociated and analyzed. The immu-
noprecipitation with UCH-L1 antibody revealed -synu-
clein monomer and a 34 kDa species that was immu-
noreactive to both -synuclein (Figure 2C, eluent
fractions) and ubiquitin (data not shown) antibodies. The
MW of this species is consistent with diubiquitylated
-synuclein (see below). The fact that UCH-L1 coimmu-
noprecipitates with free and ubiquitylated -synuclein
suggests that either one may be a substrate of UCH-
L1. This possibility contrasts with expectations based on
the optimal in vitro substrates, which are ubiquitylated
peptides and amino acids, not ubiquitylated proteins
(Larsen et al., 1996, 1998).
Figure 1. A Structural Model for the UCH-L1-Ubiquitin Complex
Does Not Explain the Protective Effect of the S18Y Polymorphism
The sequence of UCH-L1 is shown, mapped onto the determined Overexpression of UCH-L1 Variants in COS-7
structure of the highly homologous (52% identity) UCH-L3 com- Cells Leads to a Buildup of -Synuclein
plexed to the inhibitor ubiquitin aldehyde (SwissPdbViewer V. 3.7b2) Having demonstrated that UCH-L1 and -synuclein co-
(Johnston et al., 1997, 1999). Residue 93 is proximal to the active
localize and interact in brain, we sought to determinesite nucleophile (C90), while S18 is distal from the active site and
the potential effect of this interaction on the cytoplasmicfrom the ubiquitin binding site (Johnston et al., 1997, 1999).
degradation of -synuclein. COS-7 cells, which do not
normally express detectable levels of -synuclein or
UCH-L1, were cotransfected with -synuclein and histi-A significant portion (2%–5%) of both UCH-L1 and
-synuclein were found in the synaptic vesicle fraction, dine-tagged ubiquitin. Treatment with the proteasome
inhibitor lactacystin (Fenteany et al., 1995) increased, bytogether with the synaptic vesicle markers synapsin,
synaptotagmin I, and synaptophysin (Figure 2A). The 5-fold, the level of -synuclein, consistent with previous
reports (Figure 3A, lane 1 versus lane 2; Bennett et al.,synaptic vesicle localization of UCH-L1 is consistent
with the fact that it is O-glycosylated in nerve terminals 1999). Cotransfection of these cells with wt or I93M
UCH-L1 variants increased -synuclein levels by 2.5-(Cole and Hart, 2001). UCH-L1 and -synuclein were
Figure 2. A Fraction of UCH-L1 Is Localized to Synaptic Vesicles and Interacts with -Synuclein and Ubiquitylated -Synuclein
(A) UCH-L1 associates with synaptic vesicle. Different fractions from synaptic vesicle (S3, P3, LS1, LP1, LS2, and LP2) were subjected to
Western blotting with antibodies against UCH-L1, synuclein, synapsin I, synaptotagmin I, and synaptophysin. LP2 was the fraction of synaptic
vesicle.
(B) -synuclein coimmunoprecipitates with UCH-L1 in SV fraction. The supernatant after immunoprecipitation with UCH-L1 antibody was
compared to the precipitated fraction (eluent). Western blotting was performed with SYN-1 antibody.
(C) Immunoprecipitation of -synuclein with UCH-L1 or synuclein antibodies. The supernatant after immunoprecipitation was compared to
the precipitated complexes, after dissociation (eluent). Western blotting was performed with the -synuclein antibody SYN-1. The 34 kDa
species marked with an asterisk in (C) may be equivalent to the major substrate in Figure 4 (the former lacks a His tag). The control lane
showed immunoprecipitation without any antibody.
UCH-L1 and Parkinson’s Disease Susceptibility
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Figure 3. Expression of UCH-L1 or I93M Promotes Buildup of -Synuclein in Transfected Cells
(A) COS-7 cells were transfected with plasmids as indicated. The proteasome inhibitor lactacystin (LC) was added 48 hr after transfection.
Total cell lysates were analyzed by Western blotting.
(B) The relative amount of 16 kDa -synuclein (syn-1) was quantified by NIH Image program and normalized against the amount of actin. The
y axis (relative amount of undegraded -synuclein) reports the amount of -synuclein as compared to the LC-treated samples.
fold (Figure 3B), but cotransfection with S18Y had little, -synuclein-containing conjugate was a 34 kDa spe-
if any effect (50% increase). In every case, treatment cies, probably the diubiquitylated species (see asterisk,
of the UCH-L1-transfected cells with lactacystin added Figure 4A). Addition of UCH-L3 to the mixture of ubiqui-
to the UCH-L1 effect, to produce comparable levels of tylated species had little effect, though a small amount
-synuclein as in the LC-treated untransfected cells. of free -synuclein was produced after a 2 hr incubation
This result indicates that UCH-L1 transfection does not (data not shown). In contrast, UCH-L1 rapidly consumed
increase -synuclein expression and that accumulation the -synuclein-ubiquitin conjugates, especially the 34
of-synuclein resulted from inhibition of its degradation. kDa species (this species approximately comigrates
Under similar conditions, overexpression of wt and with the coimmunoprecipitating species in Figure 2C),
treatment with a different proteasome inhibitor, MG132, producing a trace amount of free -synuclein in the
also synergistically increased the accumulation of process. Surprisingly, the major products of UCH-L1
-synuclein-ubiquitin conjugates (see Supplemental treatment were high-molecular-weight -synuclein-
Data at http://www.cell.com/cgi/content/full/111/2/209/ ubiquitin conjugates, presumably formed by the net
DC1). Accumulation of -synuclein is unlikely to result addition of ubiquitin to mono- and diubiquitylated
from the hydrolytic activity of UCH-L1, since (1) hy- -synuclein (free -synuclein did not appear to be a
drolase activity is expected to promote protein degrada- substrate for chain extension [see below]). The possibil-
tion by recycling free ubiquitin (Larsen et al., 1996, 1998), ity that UCH-L1, as opposed to a contaminating ligase,
(2) the effects of I93M and wt were indistinguishable, was directly responsible for polyubiquitin chain exten-
whereas I93M is a much less active hydrolase (Leroy et sion (red arrow in Figure 4A), was strengthened by the
al., 1998), and (3) S18Y, which has comparable hydrolytic observation that UCH-L3 treatment of the same crude
activity as wt in vitro (see below), does not cause signifi- mixture did not result in chain extension.
cant accumulation. Regardless of the molecular mecha- The possibility that UCH-L1 itself possesses “ubiquityl
nism for the effect, it is consistent with a model in which ligase” activity is mechanistically reasonable (Figure
S18Y reduces a toxic function of UCH-L1, since in- 4B). Rather than reacting with water, the ubiquityl-
creased accumulation of -synuclein is likely to be toxic, enzyme thioester (or acyl enzyme), an intermediate in
and the protective variant S18Y causes less accumula- the hydrolysis reaction, may be able to react directly
tion than wt UCH-L1. with a nucleophilic lysine of another ubiquitin to produce
a ubiquitin-ubiquitin amide bond. In contrast to the well-
characterized pathway of “biological” ubiquitylation (us-UCH-L1 Seems to Ubiquitylate -Synuclein-
ing the E1, E2, and E3 ligases), which requires activationUbiquitin Conjugates
of free ubiquitin as an AMP ester in order to form theThe unexpected outcome of the cell culture experiments
acyl enzyme (Pickart, 2001; Weissman, 2001), UCH-L1(Figure 3) suggested to us that UCH-L1 could have an
ligase activity does not require ATP, since the acyl en-unreported activity that is responsible for the inhibition
zyme can be derived directly from cleavage of a ubiquitinof -synuclein degradation. To determine the nature of
C-terminal amide (Figure 4B). The proposed ligationthis activity, -synuclein was conjugated to histidine-
mechanism is reminiscent of other hydrolytic enzymestagged ubiquitin using a crude cell-free system (Figure
(e.g., proteases) that can also catalyze amide bond for-4A; Ciechanover et al., 1978). The crude products of
mation under extreme in vitro conditions. However, thisthe cell-free ubiquitylation were fractionated by nickel
may be the first example of catalysis of amide bondaffinity chromatography, which was expected to isolate
formation under physiologically reasonable conditions,all covalent ubiquitin conjugates and, possibly, other
proteins that tightly bind to ubiquitin. The predominant suggesting that it could occur in vivo.
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Figure 4. UCH-L1 Seems to Extend Polyubiquitin Chains, Specifically Those Ligated to -Synuclein
(A) Reaction of wt UCH-L1 with ubiquitylated -synuclein (produced by treatment of -synuclein with His6-tagged ubiquitin in Rabbit reticulocyte
lysate). Control, under identical conditions, showed little change.
(B) Model to explain the mechanisms of UCH-L1 ligase and hydrolase activities.
UCH-L1 Has Concentration-Dependent Ubiquityl reduced ability to form the acyl enzyme. Amino acid
changes at residue 18 had a significant effect on ligaseLigase Activity That Is Reduced in the Case
of S18Y, the “Protective” Variant activity, with wt and S18A having5-fold greater activity
than S18Y (Figure 5C). Moreover, the ratio of ligase activ-Recombinant human UCH-L1 proteins corresponding to
the three characterized UCH-L1 genes (S18/I93  wild- ity to the total acyl enzyme formation decreased on
dilution of wt and S18A, indicating that this activity istype [wt], S18/M93 I93M [Leroy et al., 1998], and Y18/
I93 S18Y); a point mutant of wt containing the mouse/ not derived from the monomeric enzymes. This result
can be explained by a model in which the ligase activityrat/horse amino acid, Ala, at position 18 (S18A); and
human UCH-L3, the highly homologous (55% identical) is derived from a dimeric (and/or oligomeric) form of
UCH-L1 that is increasingly populated at higher enzymesystemic variant, were expressed in E. coli and purified
to apparent homogeneity (Larsen et al., 1996). All pro- concentrations (see below). No ligation was observed
when free ubiquitin was replaced with free -synucleinteins had hydrolytic activity toward a fluorogenic ubiqui-
tin C-terminal amide, with the Vmax for UCH-L3 being (data not shown), indicating that the ligase recognizes
ubiquitin as the amine component of the reaction (Figure200-fold greater than that of the four UCH-L1 variants
(see Experimental Procedures and Supplemental Data 4B). To determine if a specific Lys residue was preferen-
tially ubiquitylated, wt ubiquitin was replaced in the incu-at http://www.cell.com/cgi/content/full/111/2/209/DC1).
Of the four UCH-L1 variants, only I93M had significantly bation with K63R ubiquitin, drastically reducing the
amount of ubiquitin dimer product (Figure 5D). This re-different hydrolytic activity, 50% of the three others
(Leroy, et al., 1998). sult indicated that Lys63 may be the primary ubiquityl
acceptor residue, in contrast to the E2/E3 ligases in-To test the possibility that UCH-L1 could be a ubiquityl
ligase (see Figure 4B), we incubated the enzyme (0.4–3 volved in proteasomal degradation, which ubiquitylate
Lys48 of the “nucleophilic” ubiquitin.M) with ubiquitin AMC amide (3 M) in the presence
of 50 M free ubiquitin (this concentration is physiologi-
cally reasonable [Chain et al., 1995; Mastrandrea et al., The Ubiquityl Ligase Activity of the S18 Variants
Correlates to Their Tendency to Dimerize1999]). After 2 hr, at which time ubiquitin AMC amide
had been completely consumed (data not shown), the Analytical ultracentrifugation (AU) was employed to
measure the oligomerization of each UCH variant (Figureincubation was analyzed by SDS-PAGE, with detection
by Coomassie blue staining (Figure 5A). In the case of 6 and Supplemental Data at http://www.cell.com/cgi/
content/full/111/2/209/DC1). This sensitive techniquewt, but not UCH-L3, a significant amount of diubiquitin
was produced (Figure 5B). I93M produced approxi- allows assessment of the distribution of oligomeric spe-
cies in solution and determination of their molecular sizemately 60% as much dimer as wt, consistent with its
UCH-L1 and Parkinson’s Disease Susceptibility
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Figure 5. ATP-Independent Ubiquitin Liga-
tion Is Catalyzed by UCH-L1 Variants
(A) 3 M ubiquitin-AMC and 50 M wt ubiqui-
tin were combined with 1 M of UCH-L1,
I93M, or UCH-L3. Fluorescence emission in-
tensity progress curve (not shown) indicated
that the Ub-AMC was completely consumed
within 1 hr. After incubation at 37C for 2 hr,
reaction products were resolved on 14% or
16% Tris-Glycine SDS gel stained with Coo-
massie brilliant blue. Only lanes that con-
tained UCH-L1, Ub-AMC, and wt Ub (also see
Supplemental Data at http://www.cell.com/
cgi/content/full/111/2/209/DC1) yielded di-
meric ubiquitin.
(B) Intensity of Ub2 band in each reaction,
normalized to the Ub2 band intensity in the
wt UCH-L1 incubation.
(C) Intensity of Ub2 band in each reaction,
normalized to the Ub2 band intensity in the 3
M wt UCH-L1 reaction: wt UCH-L1 (black),
S18A (dot), and S18Y (gray).
(D) Use of the K63R variant of ubiquitin re-
sulted in 80% reduction of ubiquitin dimer
product.
and does not require a reporter group. UCH-L3 was series showed no differences in ligase or hydrolase ac-
tivity [see Supplemental Data at http://www.cell.com/completely monomeric (2.3S, MW  24 [ 1] kDa) at
a concentration of 27M (far in excess of the concentra- cgi/content/full/111/2/209/DC1]). This finding strengthens
the case that UCH-L1 ligase activity partly determinestion at which ligase activity was detected). In contrast,
wt UCH-L1, an active ligase, populated a dimer (red PD susceptibility.
curve in Figure 6, 15% of total wt, 4S, calc. MW  47
[ 2] kDa) and a higher-order oligomer (green curve,
S18Y Inhibits the In Vitro Ligase Activity of I93M in
5%, 8S) at 7 M. The population of both oligomers
Trans, Suggesting a Possible Explanation for theincreased with protein concentration, and UCH dimer
Incomplete Penetrance of the I93M Mutationbecame the predominant species at 70M in the case of
The possibility of an indirect interaction between thewt (see Supplemental Data). The protective polymorphic
polymorphism at position 18 and the I93M mutation isvariant, S18Y, which did not show significant ligase ac-
suggested by the incomplete penetrance of the mutationtivity, was completely monomeric at 10 M, although
(Figure 7B). Specifically, the father of the two effecteddimer was detected at 28 M (see Supplemental Data).
individuals (asterisk in Figure 7B), who is the presumedAs a complement to AU, higher oligomers were also
carrier of I93M, did not develop PD. The genotype ofdetected by native gel electrophoresis; they were much
the two characterized I93M-carrying individuals with re-more prominent in the case of wt, as compared to S18Y
spect to position 18 was not reported (Leroy et al., 1998).at concentration of 25M (see Supplemental Data). Like
We set out to test the proposition that the incompletewt, the S18A variant also contained a significant amount
penetrance may result from a modifying effect of oneof dimer at 13 M. Thus, the tendency for UCH-L1 to
S18Y allele, and that the mechanism of modificationdimerize correlated with the ligase activity. The I93M
could be reduced ligase activity.protein, which showed reduced ligase activity as com-
The 1:1 wt/I93M mixture, a possible model of the ef-pared to wt, also showed a reduced population of dimer
fected heterozygotes (Leroy et al., 1998), showed a hy-as compared to wt.
drolase activity (blue bars in Figure 7C) that was interme-
diate between that of the two enzymes, comparable to
the sum of the monomeric hydrolases. The ligase activityThe Dose-Dependent Effect of the Protective
Allele Is Mirrored by the Effect of S18Y on of this mixture was also intermediate between wt and
I93M (gray bar, Figure 7C). The 1:1 S18Y/I93M mixturethe In Vitro Ligase Activity of Wild-Type
The suggested relationship between UCH-L1 ligase ac- had comparable hydrolytic activity (blue) but signifi-
cantly reduced ligase activity (gray) relative to the wt/tivity and enzyme dimerization prompted us to examine
the in vitro enzymatic activities of 1:1 mixtures of UCH- I93M mixture. If ligase activity confers susceptibility,
then the S18Y polymorphism could protect against I93ML1 variants. Three incubations were set up to mimic the
common human genotypes with respect to the residue in trans. This effect may explain the incomplete pene-
trance of I93M. Furthermore, the nonadditivity of ligase18 polymorphism: S18Y/S18Y, wt/S18Y, and wt/wt (Fig-
ure 7A). Within this series, hydrolytic activity was con- activity is consistent with our proposal that ligase activ-
ity is a property of the dimer, and not the UCH-L1stant (data not shown), but ligase activity increased,
correlating to increasing risk (the analogous S18A/wt monomer.
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Figure 6. Analytical Ultracentrifugation Demonstrates that UCH-L1 Variants Differ with Respect to Their Oligomerization Behavior
The apparent distributions of the sedimentation coefficient (g(s*)) for UCH-L3, UCH-L1 wt, S18Y, S18A, and I93M and obtained from the time-
derivative analysis (Stafford, 1992) of the sedimentation velocity data for each protein. The black line reflects the best least squares fit of the
data (O) to a single (UCH monomer, blue), two (monomer-dimer), or three species (monomer-dimer-oligomer) model using a Gaussian function.
Attempts to fit the wt, I93M, and S18A data to a single species model failed to yield a good fit.
Discussion dopaminergic neurons, as is PD cell loss, strengthens
the case that they model the PD pathogenic pathway.
We report here a novel in vitro ligase activity of theAn important line of defense against neurotoxic protein
aggregation is a fully functional protein degradation UCH-L1 dimer that offers a simple mechanistic explana-
tion for the fact that the S18Y polymorphism reducespathway, which includes UCH-L1 (Lam et al., 2000; Lay-
field et al., 2001). In addition to Parkinson’s disease, susceptibility to PD. There is precedent for a “dimeric”
ubiquityl ligase: the crystallographically characterizedUCH has been implicated in two other neurodegenera-
tive diseases that may also be triggered by protein ag- Mms2/Ubc13 heterodimer (Moraes et al., 2001; VanDe-
mark et al., 2001). Mms2 and Ubc13 are E2 homologs,gregation (Rochet and Lansbury, 2000): spinocerebellar
ataxia (SCA), in which a UCH mutant is a genetic en- but the former lacks an active site cysteine and is thus
an inactive hydrolase. The Mms2-Ubc13 heterodimerhancer of degeneration in SCA transgenic flies (Fernan-
dez-Funez et al., 2000), and Huntington’s disease, in has ligase activity and its cocrystal appears to be capa-
ble of binding two ubiquitin molecules in an orientationwhich the UCH-L1 S18Y polymorphism is linked to age
at onset (Naze et al., 2002). Other gene products in the that would allow ubiquityl transfer from the Ubc13 thio-
ester to K63 of a second ubiquitin, which is the preferredprotein degradation pathway have also been implicated
in PD: an active site deletion in the parkin gene product, ligation chemistry. It is interesting that the UCH-L1 dimer
also ubiquitylates Lys63. Whether this ligation chemistryan E3 ligase critical in preparing proteasome substrates,
results in juvenile-onset Parkinsonism (Kitada et al., is important to PD pathogenesis is the subject of the
speculation below.1998). Biochemical studies of PD brain demonstrate im-
paired proteasome activity (McNaught et al., 2001). Inhi- Although our cell culture studies demonstrate that the
UCH-L1 ligase activity could be pathogenic for PD, it isbition of the proteasomal pathway in cultured neurons
and rat brains by lactacystin (a proteasome inhibitor) possible that there may be a biological role for this
activity. Given the high hydrolase activity of UCH-L3, it is(McNaught et al., 2002a) or by ubiquitin aldehyde (a
UCH inhibitor) (McNaught et al., 2002b) causes inclusion attractive to imagine that UCH-L1 may not be produced
solely for its relatively weak hydrolase activity and thatformation and cell death (Rideout et al., 2001; Tofaris
et al., 2001). The fact that these effects are selective for its ligase activity could have evolved to be regulated
UCH-L1 and Parkinson’s Disease Susceptibility
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Figure 7. Ubiquityl Ligase Activity of Mixtures of UCH-L1 Variants Supports a Correlation between This Activity and PD Susceptibility
1:1 mixtures of two variants, models of heterozygotes, were compared to pure variants of equal total [UCH-L1], models of homozygotes.
Ligation (gray columns) and hydolysis (blue columns) are reported as in Figure 3.
(A) Increasing ligase activity correlates to increasing risk of PD.
(B) The family in which the I93M mutation was discovered (taken from Leroy et al., 1998), demonstrating that I93M mutation is not 100%
penetrant (squares  males, shaded  PD). Note the unaffected father, presumed to be the carrier of I93M. Genotypes are available only for
the most recent generation, with the results shown (the polymorphism at position 18 was not recognized at the time that this information was
reported).
(C) The S18Y variant effects ligase (but not hydrolase) activity in trans, suggesting an explanation for the incomplete penetrance of I93M.
posttranslationally. Dimerization-dependent ligase ac- models is operative. We assume that, in order to avoid
PD, -synuclein levels are normally kept under the criti-tivity (Figure 8A) could be regulated by any number of
cytoplasmic events, such as membrane (synaptic vesi- cal concentration for oligomerization (dashed line in Fig-
ure 8B; Rochet and Lansbury, 2000) by proteasome-cle) binding, which would be expected to promote di-
merization. The loss of control of the ligase activity could dependent degradation. Degradation is initiated by
elaboration of a K48-linked polyubiquityl chain in anbe pathogenic.
The mechanism by which UCH-L1 ligase activity pro- ATP-dependent process that requires E1, E2, and E3
ligases (Figure 8B, to the left). UCH-L1 may be able tomotes PD pathogenesis is not clear, but several models
should be considered. Although the models discussed elaborate K63-linked polyubiquityl chains (note different
pattern in Figure 8B) on -synuclein in a dimerization-below are, in principal, experimentally distinguishable,
determination of the precise mechanism will be difficult dependent, ATP-independent process. The UCH-L1 li-
gase activity could produce an elevation of the cyto-since it is likely that a combination of these (and other)
Figure 8. Several Speculative Models Could
Explain the Apparent Pathogenicity of UCH-
L1 Ligase Activity
(A) A model for the two activities of UCH-L1.
The hydrolytic activity (green) may be benefi-
cial, while the ligase activity (red), which is
more sensitive to increases in UCH-L1 ex-
pression, could be harmful. Thus, both loss
of UCH-L1 hydrolytic activity and gain of
UCH-L1 ligase activity could deplete the pool
of free ubiquitin and compromise the ubiqui-
tin-dependent degradation pathway. The
ubiquityl donor can be a peptide or protein
conjugate, and thus no “activation” of its C
terminus, by ATP, for example, is required.
UCH-L1 ligase activity could produce unde-
gradable, K63-linked (indicated by dotted
background) polyubiquitin chains that could
inhibit proteasomal activity.
(B) Evolution strives to divert the flux of
-synuclein away from protofibrillar aggre-
gates and the “PD” pathway. However, these
models, discussed thoroughly in the text,
suggest several mechanisms whereby PD
can be promoted by UCH-L1 ligase activity. The shading of the blue spheres, which represent ubiquitin molecules, was chosen to emphasize
differences in interubiquitin amide linkages: the checked pattern indicates K48 linkage, whereas the dotted background indicates K63 linkage.
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plasmic concentration of -synuclein by inhibiting its Ultimately, trials of such inhibitors in animal models of
“normal” degradation. Inhibition of the proteasome PD will test the hypothesis proposed here.
could be achieved by either the K63-linked polyubiquity-
Experimental Procedureslated -synuclein (1 in Figure 8B) or K63 polyubiquitin
chains formed by repeated rounds of ubiquitin ligation
Proteins and Antibodiesas shown in Figure 8 (2 in Figure 8B). There is precedent Plasmids for prokaryotic expression of UCH-L1 and I93M were a
for the later mechanism (Hofmann and Pickart, 2001). gift from K. Wilkinson, and the plasmid for expression of S18Y was
The magnitude of inhibition needed to produce a signifi- generated using QuickChange Mutagenesis Kit (Strategene). Anti-
bodies used for immunoblotting were monoclonal anti--synucleincant effect need not be great, since it is possible to
(15–123, SYN-1, Transduction Labs, 1:2000) and monoclonal anti-promote the aggregation of -synuclein by “molecular
ubiquitin (mUb, Chemicon Intl., 1:15,000). Recombinant -synucleincrowding” (Shtilerman et al., 2002), that is, by increasing
and wt UCH-L1, S18Y, and I93M were expressed and purified asthe total cytoplasmic protein concentration by a small
reported. Concentrations of UCH enzymes were determined by
amount. Crowding will promote processes that have a amino acid analysis. Recombinant UCH-L3 was both a gift from H.L.
negative volume of reaction, for example, -synuclein Ploegh and purchased from Boston Biochem (Cambridge, MA).
fibrillization (Shtilerman et al., 2002), and will effectively
Isolation of Synaptic Vesiclesdecrease the -synuclein concentration threshold (3 in
Synaptic vesicle preparation was performed according to the pub-Figure 8B). It is also possible that K63 polyubiquitylation
lished protocol (Hell and Jahn, 1998). S3, P3, LS1, LP1, LS2, andof -synuclein (like both PD-linked mutations) may pro-
LP2 fractions were subjected to Western blotting using UCH-L1mote formation of pathogenic protofibrils (4) and/or in-
antibody (Chemicon), -synuclein (Transduction Lab), synaptophy-
hibit the protofibril-to-fibril/Lewy body transformation, sin (Transduction Lab), synaptotagmin I (Transduction Lab), and
which may be detoxifying (5). Mechanism 5 is prece- synaptin I (Chemicon). In the cases for synaptotagmin I and synapto-
dented in the case of another -synuclein adduct: the physin I, rat cerebrum lysate purchased from Transduction Lab was
added as the positive control.dopamine--synuclein adduct inhibits the protofibril-to-
fibril transformation, leading to accumulation of protofi-
Rat Brain Preparation and Immunoprecipitationbrils (Conway et al., 2001). Finally, one must consider
Whole brains from rats (Sprague-Dawley) in equal volume of UCHthe possibility that the K63-linked polyubiquitylated
buffer were homogenized using 1.0 mm glass beads (Biospec Prod-
-synuclein species could itself be neurotoxic (6). This ucts) with Mini-Beadbeater (Biospec Products). The lysate was cen-
mechanism, while unprecedented, is consistent with the trifuged at 14,000 rpm for 10 min and the supernatant was manually
fact that elevation of ligase activity and elevation of loaded onto a 1 ml HiTrap Q XL column. The column was then
installed onto FPLC system and washed with 5 column volume of[-synuclein] are synergistically pathogenic, since both
UCH buffer. Proteins were eluted with a gradient of 0 to 1 M NaClwould boost the concentration of the toxic species (this
in UCH buffer over 60 column volume. A small fraction of synucleinis also true of mechanisms 1–5). Of these six possible
was retained in the column and they were coeluted with UCH-L1
mechanisms (the list is not exhaustive), 1 and 2 are (from 200 to 300 mM NaCl gradient). The fractions that contained
clearly consistent with the effect of UCH-L1 variants in UCH-L1 and synuclein were determined by Western blotting. They
cell culture reported here. It is also possible that were combined and dialyzed in UCH buffer at 4C overnight. For
each immunoprecipitation assay, 0.5 ml of combined UCH-L1/-synuclein protofibrils, which would accumulate in sce-
synuclein fractions was added with 1 l of SYN-1, Anti PGP9.5, ornarios 4 and 5, could inhibit the proteasome (7 in Figure
buffer. Binding reactions were sat at RT for 1 hr prior to addition of8B), as has been demonstrated for other protein aggre-
protein G agarose (Boehringer Mannheim). The mixtures were ro-gates (Bence et al., 2001). Overexpression of a PD-linked
tated using Labquake Shaker (Barnstead) for half an hour. The aga-
mutant from of -synuclein in PC12 cells causes a de- rose was isolated by centrifugation and washed with UCH buffer
crease in proteasome activity (Engelender et al., 2001). three times. Proteins were eluted with SDS loading buffer and result
Thus, it is clear that -synuclein aggregation and was analyzed using Western blot.
-synuclein degradation are linked and that small per-
Transfection of COS-7 Cells with UCH-L1, Ubiquitin,turbations of either process by UCH-L1 could amplify
and -Synucleinand produce a significant overall effect.
The plasmid for eukaryotic expression of -synuclein (pcDNA) wasThe traditional loss-of-function versus gain-of-func-
constructed by insertion of the cDNA for human -synuclein into
tion analysis of a disease-associated mutation is based pcDNA3.1() (Invitrogen). UCH-L1 and its variants were also cloned
on a one gene  one enzymatic activity model. In the into pcDNA3.1 with restrict enzymes Xho I and Hind III. UB-HIS
case of UCH-L1, we have demonstrated that one gene pWC7 was a generous gift from D. Finley. COS-7 cells were grown
in DMEM 10% FBS and were transfected with plasmids usingcan encode two related enzyme activities. UCH-L1 pos-
FuGene6 (Roche Molecular Biochemicals). Transfected cells weresesses a beneficial hydrolase activity and a dimeriza-
cultured at 37C for 48 hr before being treated with 35 M lactacys-tion-dependent ligase activity that is at least partly
tin, MG132, or DMSO. After 24 hr of incubation, the cells were lysedpathogenic. Decreasing UCH-L1 expression could have
using 8 M Urea, 100 mM NaH2PO4, 10 mM Tris-HCl (pH 8.0), anda therapeutic benefit, since the hydrolase activity would 0.5% Triton X-100. Cell lysates were resolved on SDS-PAGE and
decrease less rapidly than ligase activity (the former analyzed using Western blot.
would decrease linearly as a function of [UCH-L1], while
the latter would decrease as a function of [UCH-L1]2 ). Ubiquitylation of -Synuclein in Rabbit Reticulocyte Lysate
Crude rabbit reticulocyte-rich blood was obtained from Pel-FreezAn ideal PD therapeutic would, like the protective S18Y
Biologicals. Rabbit reticulocyte lysate (RRL) was prepared ac-polymorphism, inhibit the ligase activity and, in addition,
cording to Ciechanover et al. (1978). In a total volume of 700 l, 5promote the hydrolase activity. This could be accom-
M -synuclein and 100 M His6-ubiquitin (Affiniti Research Prod-plished by inhibiting UCH-L1 dimerization, thus increas- ucts, Ltd., Exeter, UK) were incubated in RRL in the presence of 2
ing the concentration of monomeric UCH-L1 (Figure 8). mM ATP, 50 M LC, 2 M Ubal, 2 mM DTT, 5 mM MgCl2, and
This strategy is being tested through the identification an ATP regenerating system (10 mM creatine phosphate/1 mg/ml
creatine phosphokinase). The reaction was allowed to proceed forof drug-like small-molecule UCH-L1 ligase inhibitors.
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2.5 hr at 37C before being placed on ice and quenched by 50 l Sedimentation Analysis by Analytical Ultracentrifugation
Sedimentation velocity experiments were performed in a tempera-of protease inhibitor cocktail (Sigma) and 1 mM N-ethylmaleimide
(Sigma). An equal volume of binding buffer (50 mM NaH2PO4 [pH ture-controlled Beckman XL-I. 400–420 l of protein (UCH-L3, UCH-
L1 wt, I93M, S18A, and S18Y) at the desired concentration in UCH8.0], 300 mM NaCl, 10 mM imidazole) and 500 l of a 20% slurry of
Ni-nta magnetic agarose beads (Qiagen) were added to the lysate. buffer was loaded into two-channel 1.2 cm path cell. The data were
recorded at rotor speeds of 3,000–60,000 rpm in continuous modeThis mixture was incubated at 4C overnight, then washed with
binding buffer (2  1 ml) and washing buffer (2  1 ml, 50 mM with a step size of 0.005 cm at 20C–25C. The sedimentation veloc-
ity absorbance profiles were then analyzed to obtain the apparentNaH2PO4 [pH 8.0], 300 mM NaCl, 20 mM imidazole). The His6-ubiqui-
tin conjugates of -synuclein were eluted from the agarose beads distribution of sedimentation coefficients g(s*) for all the quaternary
structures in solution using the DCDT software provided by Philousing 2  90 l of elution buffer (50 mM NaH2PO4 [pH 8.0], 300 mM
NaCl, 250 mM imidazole) and dialyzed into PBS overnight at 4C (Stafford, 1992). The observed sedimentation coefficient, s, was
corrected to standard conditions (water at 20C). The partial specificusing a Slide-A-Lyzer mini dialysis unit with 10,000 MWCO (Pierce).
Protein samples were resolved using 14% Tris-glycine (TG) or 4%– volume of UCH-L1 (0.735 cm3/g) was estimated based on the partial
specific volumes of its component amino acid residues.20% TG for high-molecular-weight proteins. The proteins were
transferred to polyvinylidine difluoride (PVDF), and all membranes
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